Home Compare ALNY vs CAMX.ST
Stock Comparison · Industry comparison · Biotechnology

Alnylam Pharmaceuticals vs Camurus AB (publ): Which Stock Looks Stronger in 2026?

Alnylam Pharmaceuticals holds the cleaner structural position, with the lead spread across growth and stability. Camurus AB (publ) still has the edge on profitability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ALNY: Nasdaq 100, CAMX.ST: STOXX 600).

Updated 2026-06-14

The lead is spread across growth and stability, rather than sitting in one isolated gap. Alnylam Pharmaceuticals, Inc. leads by 17 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Biotechnology

This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and CAMX.ST share the same industry classification.

For a similarity-based comparison, see how Alnylam Pharmaceuticals and Camurus AB (publ) each position within their functional peer groups in AssetNext.

Peer-Relative Score
ALNY
Alnylam Pharmaceuticals, Inc.
66
Peer-Score
Signal qualitylow
Peer basis: Nasdaq 100
vs
CAMX.ST
Camurus AB (publ)
49
Peer-Score
Signal qualityHigh
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: ALNY vs CAMX.ST Profitability 71 86 Stability 71 45 Valuation 42 30 Growth 88 24 ALNY CAMX.ST
Gap Ranking
#1 Growth +64
#2 Stability +26
#3 Profitability +15
#4 Valuation +12
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ALNY and CAMX.ST Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ALNYCAMX.ST Relative valuation Structural strength

Neither company combines the stronger profile with the cheaper valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Alnylam Pharmaceuticals, Inc. ranks near the top of the group on growth; Camurus AB (publ) sits in the weaker half.
Stability
On stability, the edge is clear — both rank well, but Alnylam Pharmaceuticals, Inc. sits noticeably higher.
Growth — Dominant Gap
ALNY
88
CAMX.ST
24
Gap+64in favour of ALNY

One company is still expanding while the other is contracting, which creates a very wide growth split.

What keeps the gap from being one-sided

Profitability still favours Camurus AB (publ), with a 8.6-point operating margin advantage keeping the comparison from looking fully resolved.

What this means for the comparison

The lead is built on both growth and stability — though profitability still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the ALNY vs CAMX.ST comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how ALNY and CAMX.ST each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.